Advertisement
Advertisement
U.S. Markets open in 2 hrs 22 mins
Advertisement
Advertisement
Advertisement
Advertisement

TC Biopharm (Holdings) Plc (TCBP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.3623-0.0326 (-8.26%)
At close: 04:00PM EDT
0.4008 +0.02 (+4.67%)
Pre-Market: 07:06AM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3949
Open0.4022
Bid0.0000 x 1000
Ask0.0000 x 3000
Day's Range0.3623 - 0.4089
52 Week Range0.3300 - 3.5000
Volume374,548
Avg. Volume836,791
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire

    TC Biopharm Announces Closing of $4 Million Underwritten Public Offering

    TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer indications, today announced the closing of its previously announced underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million,

  • PR Newswire

    TC BioPharm Announces Pricing of $4 Million Underwritten Public Offering

    TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer, today announced the pricing of an underwritten public offering of 10,000,000 American Depositary Shares (the "ADSs"), each ADS representing one ordinary share of the Company, at a public offering price of $0.40 per ADS, for aggregate gross proceeds of $4 million, prior to deducting underwriting d

  • PR Newswire

    TC BioPharm Highlights Need for Disruptive Treatment as Acute Myeloid Leukemia Cases Rise Globally

    TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer treatment, today announced that Acute myeloid leukemia (AML) diagnoses have risen globally according to a recent study entitled, "EPR22-104: A Comparison of the Burden of Leukemia Amongst Various Regions of the World, 1990-2019," published in the Journal of the National Comprehensive Cancer Networ

Advertisement
Advertisement